Treating Diabetes: Designing the Once-Weekly and Oral GLP-1 Semaglutide
Oct 24, 2019 | 2:00 PM - 3:00 PM
|
Join Jesper Lau, Vice President of Research Chemistry at Novo Nordisk A/S to learn why the discovery of Semaglutide is a fantastic example of on how technology and biologic understanding have developed a superior peptide for the treatment of diabetes.
Register